ClinicalTrials.gg
CompletedNCT03116841VISTAEXEUpdated Mar 29, 2019Results posted

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

A Phase 4 interventional study of Vonoprazan in Reflux Esophagitis, sponsored by Takeda. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Esophagitis, Peptic by Takeda — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · Takeda.

Started
2017
the only one that year
Phase 4
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Esophagitis, Peptic by Takeda, this one is the only one that started in 2017, is the only one in phase 4, and was the 7th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 10 studies in Esophagitis, Peptic by Takeda is open now. The open studies under Esophagitis, Peptic, anywhere →

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Esophagitis, Peptic by Takeda as a file.
02

Study summary

The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality Index (PSQI) global score despite the maintenance treatment with PPI other than vonoprazan.

Read the detailed description

The purpose of this study is to evaluate the effect of vonoprazan on sleep disturbance in the participants under maintenance treatment for reflux esophagitis with proton pump inhibitor (PPI) other than vonoprazan after initial treatment.

Participants who have been diagnosed as reflux esophagitis based on Los Angeles (LA) Classification Grades A to D, undergoing maintenance treatment with PPI other than vonoprazan after initial treatment, and with Pittsburgh Sleep Quality Index (PSQI) global score >= 6.0 at enrolment (VISIT 1) will be eligible for study entry and will be administered vonoprazan 20 mg once daily for 8 weeks.

Planned number of participants is 25. The study period is 9 weeks. The number of visits is 6visits.

03

Conditions studied

  • Reflux Esophagitis

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who completed the initial treatment with PPIs (esomeprazole, omeprazole, rabeprazole, or lansoprazole) and have received high dose PPIs (esomeprazole 20 mg, omeprazole 20 mg, rabeprazole 10 mg, or lansoprazole 30 mg) for more than 8 weeks at the time of as maintenance treatment for LA Classification Grades A to D reflux esophagitis.
  2. Participants who have heartburn and/or regurgitation.
  3. Participants with reflux esophagitis related sleep disturbance, fulfilling at least one of following in a week before the baseline/start of administration.

    • Difficulty in falling asleep for > = 3 nights
    • Nocturnal awaking or early morning awaking for > = 3 nights
  4. Participants whose heartburn and/or regurgitation at the time of informed consent were alleviated from initial treatment.
  5. Participants with PSQI global score > = 6.0
  6. Participants who, in the opinion of the investigator, are capable of understanding the content of the study and complying with the protocol requirements.
  7. Participants who can sign and date an informed consent form and information sheet prior to the initiation of the study procedures.
  8. Male or female participants aged 20 years or older at the time of informed consent.
  9. Therapeutic category: Ambulatory

Exclusion criteria

Exclusion Criteria:

  1. Participants with Zollinger-Ellison syndrome.
  2. Participants with diseases that affect sleep (, bronchitis asthma, sleep apnea syndrome, mental disorder, etc.)
  3. Nightshift workers.
  4. Participants who have a plan to travel beyond three time zones during the study.
  5. Participants with a history of, concurrent, or suspicious functional dyspepsia or functional heartburn based on Rome IV criteria.
  6. Participants with history of surgery or treatment affecting gastroesophageal reflux (fundoplication or dilation for esophageal stenosis [except for Schatzki's ring], etc.).
  7. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included.
  8. Participants with a history of gastrectomy, gastrointestinal resection, or vagotomy.
  9. Participants who took antidepressant agents or anti-anxiety agents within 8 weeks before the time of .
  10. Participants who took H2 receptor antagonist within 8 weeks before the time of informed consent.
  11. Participants planning to take prohibited concomitant medications during the study period.
  12. Participants who have any of the following abnormal clinical laboratory test values at the screening (VISIT 1):

    • (ALT) or aspartate aminotransferase (AST) > (ULN)
    • (Total bilirubin) > ULN
  13. Participants with a malignant tumor.
  14. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.
  15. Participants who have serious renal diseases.
  16. Participants with the conditions listed under administration in the vonoprazan package insert.
  17. Participants participating in other clinical studies.
  18. Participants who have been determined as inappropriate participants by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Vonoprazan 20 mg

    Vonoprazan 20 mg orally administered once daily

    Drug: Vonoprazan

Interventions

06

What researchers measure

Primary outcomes

  1. Changes From Start of Administration (Week 0) in Pittsburgh Sleep Quality Index (PSQI) Global Score at End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participant (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0 to End of study (up to Week 8)

Secondary outcomes

  1. Changes From Start of Administration (Week 0) in PSQI Global Score at Week 4

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: From Week 0 to Week 4

  2. Percentage of Participants With PSQI Global Score <6.0 at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality.

    Time frame: Week 4 and End of study (up to Week 8)

  3. Changes From Start of Administration (Week 0) in C1: Sleep Quality of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  4. Changes From Start of Administration (Week 0) in C2: Sleep Latency of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  5. Changes From Start of Administration (Week 0) in C3: Sleep Duration of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  6. Changes From Start of Administration (Week 0) in C4: Sleep Efficiency of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  7. Changes From Start of Administration (Week 0) in C5: Sleep Disturbance of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  8. Changes From Start of Administration (Week 0) in C7: Daytime Dysfunction of PSQI Global Score at Week 4 and End of Study

    PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 0, Week 4 and End of study (up to Week 8)

  9. Number of Nocturnal Awakenings Assessed by a Question at Week 4, and End of Study

    Number of nocturnal awakenings was assessed by a question about nocturnal awakenings, "How Many Times Wake Up?" which was asked to each participants by investigator. Reported data were individual times for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 4 and End of study (up to Week 8)

  10. Percent Changes From Start of Administration (Week 0) in Actigraph-Measured Sleep Efficiency at Week 4, and End of Study

    Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Mean value from the past 7 days at each time point was used for calculation. Reported data were individual values for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 4 and End of study (up to Week 8)

  11. Changes From Start of Administration (Week 0) in Actigraph-Measured Sleep Latency at Week 4, and End of Study

    Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Reported data were individual values for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 4 and End of study (up to Week 8)

  12. Changes From Start of Administration (Week 0) in Actigraph-Measured Number of Nocturnal Awakenings at Week 4, and End of Study

    Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Mean value from the past 7 days at each time point was used for calculation. Reported data were individual times for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

    Time frame: Week 4 and End of study (up to Week 8)

  13. Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)

    Time frame: Up to Week 8

07

Results

Posted Mar 29, 2019

Participant flow

Participants took part in the study in Japan, from 02 August 2017 to 20 December 2017.

Participant flow — Overall Study
MilestoneVonoprazan 20mg
Started3
Completed3
Not completed0

Outcome measures

PrimaryChanges From Start of Administration (Week 0) in Pittsburgh Sleep Quality Index (PSQI) Global Score at End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participant (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0 to End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in Pittsburgh Sleep Quality Index (PSQI) Global Score at End of Study
Scores on a ScaleVonoprazan 20mg
Participant A-2
Participant B1
Participant C-6
SecondaryChanges From Start of Administration (Week 0) in PSQI Global Score at Week 4

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
From Week 0 to Week 4
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in PSQI Global Score at Week 4
Scores on a ScaleVonoprazan 20mg
Participant A-2
Participant B1
Participant C-5
SecondaryPercentage of Participants With PSQI Global Score <6.0 at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality.

Time frame:
Week 4 and End of study (up to Week 8)
Reported as:
Number · Percentage of Participants
Percentage of Participants With PSQI Global Score <6.0 at Week 4 and End of Study
Percentage of ParticipantsVonoprazan 20mg
Week 433.3
End of study66.7
SecondaryChanges From Start of Administration (Week 0) in C1: Sleep Quality of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C1: Sleep Quality of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 40
Participant A - End of study-1
Participant B - Week 40
Participant B - End of study0
Participant C - Week 4-2
Participant C - End of study-2
SecondaryChanges From Start of Administration (Week 0) in C2: Sleep Latency of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C2: Sleep Latency of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 4-1
Participant A - End of study-1
Participant B - Week 40
Participant B - End of study0
Participant C - Week 4-1
Participant C - End of study-1
SecondaryChanges From Start of Administration (Week 0) in C3: Sleep Duration of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C3: Sleep Duration of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 40
Participant A - End of study0
Participant B - Week 41
Participant B - End of study1
Participant C - Week 40
Participant C - End of study-1
SecondaryChanges From Start of Administration (Week 0) in C4: Sleep Efficiency of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C4: Sleep Efficiency of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 40
Participant A - End of study0
Participant B - Week 40
Participant B - End of study0
Participant C - Week 40
Participant C - End of study0
SecondaryChanges From Start of Administration (Week 0) in C5: Sleep Disturbance of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C5: Sleep Disturbance of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 40
Participant A - End of study0
Participant B - Week 40
Participant B - End of study0
Participant C - Week 40
Participant C - End of study0
SecondaryChanges From Start of Administration (Week 0) in C7: Daytime Dysfunction of PSQI Global Score at Week 4 and End of Study

PSQI is a self-rated questionnaire for sleep quality. It includes 18 items across 7 components; C1: Sleep quality, C2: Sleep latency, C3: Sleep duration, C4: Sleep efficiency, C5: Sleep disturbance, C6: Use of sleep medication, C7: Daytime dysfunction. Each component is scored 0-3 (0 = no difficulty, 3=severe difficulty), and total score ranging from 0 to 21. Higher scores are representing worse sleep quality. Reported data were individual scores for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 0, Week 4 and End of study (up to Week 8)
Reported as:
Number · Scores on a Scale
Changes From Start of Administration (Week 0) in C7: Daytime Dysfunction of PSQI Global Score at Week 4 and End of Study
Scores on a ScaleVonoprazan 20mg
Participant A - Week 4-1
Participant A - End of study0
Participant B - Week 40
Participant B - End of study0
Participant C - Week 4-2
Participant C - End of study-2
SecondaryNumber of Nocturnal Awakenings Assessed by a Question at Week 4, and End of Study

Number of nocturnal awakenings was assessed by a question about nocturnal awakenings, "How Many Times Wake Up?" which was asked to each participants by investigator. Reported data were individual times for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 4 and End of study (up to Week 8)
Reported as:
Number · Nocturnal awakenings
Number of Nocturnal Awakenings Assessed by a Question at Week 4, and End of Study
Nocturnal awakeningsVonoprazan 20mg
Participant A - Week 40
Participant A - End of study0
Participant B - Week 41
Participant B - End of study2
Participant C - Week 41
Participant C - End of study1
SecondaryPercent Changes From Start of Administration (Week 0) in Actigraph-Measured Sleep Efficiency at Week 4, and End of Study

Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Mean value from the past 7 days at each time point was used for calculation. Reported data were individual values for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 4 and End of study (up to Week 8)
Reported as:
Number · Percent of Change
Percent Changes From Start of Administration (Week 0) in Actigraph-Measured Sleep Efficiency at Week 4, and End of Study
Percent of ChangeVonoprazan 20mg
Participant A - Week 43.10
Participant A - End of study4.48
Participant B - Week 4-10.56
Participant B - End of study3.57
Participant C - Week 42.00
Participant C - End of study-3.17
SecondaryChanges From Start of Administration (Week 0) in Actigraph-Measured Sleep Latency at Week 4, and End of Study

Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Reported data were individual values for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 4 and End of study (up to Week 8)
Reported as:
Number · Minutes
Changes From Start of Administration (Week 0) in Actigraph-Measured Sleep Latency at Week 4, and End of Study
MinutesVonoprazan 20mg
Participant A - Week 4-10.00
Participant A - End of study-5.00
Participant B - Week 421.00
Participant B - End of study10.00
Participant C - Week 4-13.00
Participant C - End of study1.00
SecondaryChanges From Start of Administration (Week 0) in Actigraph-Measured Number of Nocturnal Awakenings at Week 4, and End of Study

Actigraph is a small device usually that records the activity level of the body by sensing physical movement and that is used especially to measure the amount and quality of sleep. Mean value from the past 7 days at each time point was used for calculation. Reported data were individual times for each participants (Participant A to C) since descriptive statistics value was not calculated due to small size population (totally 3 participants).

Time frame:
Week 4 and End of study (up to Week 8)
Reported as:
Number · Nocturnal awakenings
Changes From Start of Administration (Week 0) in Actigraph-Measured Number of Nocturnal Awakenings at Week 4, and End of Study
Nocturnal awakeningsVonoprazan 20mg
Participant A - Week 40.15
Participant A - End of study0.00
Participant B - Week 4-2.00
Participant B - End of study-1.15
Participant C - Week 40.86
Participant C - End of study1.00
SecondaryNumber of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)
Time frame:
Up to Week 8
Reported as:
Count of participants · Participants
Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)
ParticipantsVonoprazan 20mg
Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)2

Adverse events

Collected over Up to Week 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 20mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Most frequent other events
EventVonoprazan 20mg
Viral upper respiratory tractInfections and infestations1/3
Gastrointestinal disorderGastrointestinal disorders1/3

Baseline characteristics

Full Analysis Set (FAS): All participants who received at least 1 dose of the study drug for the treatment period.

Age, Customized
Age, Customized(Participants)Vonoprazan 20mg
>=20 and <80 years3
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 20mg
Female2
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vonoprazan 20mg
Region of Enrollment
Region of Enrollment(Participants)Vonoprazan 20mg
Japan3
08

Study locations

6 sites
  • Tokatsu Tsujinaka Hospital
    Abiko, Chiba, Japan
  • Amada Clinic
    Koriyama, Fukushima, Japan
  • Aoyama Clinic
    Kobe, Hyogo, Japan
  • Kashiwara Municipal Hospital
    Kashiwara, Osaka, Japan
  • Saino Clinic
    Tokorozawa, Saitama, Japan
  • Masuyama Clinic
    Otawara, Tochigi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Dec 2017, 4 months.

Results were first posted in Mar 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 17, 2017
StartActual
Aug 2, 2017
Primary completionActual
Dec 20, 2017
CompletionActual
Dec 20, 2017
Results first posted
Mar 29, 2019
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03116841
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 17, 2017
Start date
Aug 2, 2017
Primary completion
Dec 20, 2017
Completion
Dec 20, 2017
Results posted
Mar 29, 2019
Last update
Mar 29, 2019

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion